ELTX (Elicio Therapeutics) Total Stockholders Equity: $7.94 Mil (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ELTX Elicio Therapeutics Inc ELTX
26 GF Score
Price $2.84
View Full Analysis

What is Elicio Therapeutics Total Stockholders Equity?

Elicio Therapeutics ELTX -5.33% 26 Total Stockholders Equity is $7.94 Mil as of Jun. 2026. GuruFocus rates ELTX with a GF Score™ of 26/100.

Elicio Therapeutics's Total Stockholders Equity for the quarter that ended in Jun. 2026 was $7.94 Mil. It refers to the net assets owned by shareholders. It does not include minority interest.

Total Stockholders Equity is used to calculate Book Value per Share. Elicio Therapeutics's Book Value per Share for the quarter that ended in Jun. 2026 was $0.36. The ratio of a company's debt over equity can be used to measure how leveraged this company is. Elicio Therapeutics's Debt-to-Equity for the quarter that ended in Jun. 2026 was 1.78.


Elicio Therapeutics  (NAS:ELTX) Total Stockholders Equity Explanation

1. Total Stockholders Equity is used to calculate Book Value per Share.

Elicio Therapeutics's Book Value per Share for the quarter that ended in Jun. 2026 is

2. The ratio of a company's debt over equity can be used to measure how leveraged this company is.

Elicio Therapeutics's Debt-to-Equity for the quarter that ended in Jun. 2026 is

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Elicio Therapeutics Total Stockholders Equity Related Terms


Elicio Therapeutics Total Stockholders Equity Historical Data

* Premium members only.

The historical data trend for Elicio Therapeutics's Total Stockholders Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Elicio Therapeutics Total Stockholders Equity Chart

Elicio Therapeutics Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Total Stockholders Equity
Get a 7-Day Free Trial -74.54 -102.15 11.37 -11.31 1.64

Elicio Therapeutics Quarterly Data
Dec20 Mar21 Dec21 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Total Stockholders Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.83 3.82 1.64 -1.44 7.94
ELTX
26GF Score
Elicio Therapeutics Inc ELTX
Total Stockholders Equity is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
What does a Total Stockholders Equity of $7.94 Mil mean?
Elicio Therapeutics (ELTX) has a Total Stockholders Equity of $7.94 Mil as of Jun. 2026. The total amount of shareholder's equity as recorded on a company's balance sheet. View historical data for Elicio Therapeutics and its competitors.
Is Elicio Therapeutics' Total Stockholders Equity too high?
Elicio Therapeutics' current Total Stockholders Equity is $7.94 Mil. Overall, Elicio Therapeutics has a GF Score™ of 26/100, reflecting its overall financial health beyond just this single metric.
How does Elicio Therapeutics' Total Stockholders Equity compare to TELO and INO?
Elicio Therapeutics' Total Stockholders Equity of $7.94 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Stockholders Equity for a Biotechnology company?
A good Total Stockholders Equity depends on the Biotechnology industry context. However, Total Stockholders Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Stockholders Equity mean?
A high Total Stockholders Equity can signal that a stock is expensive relative to its fundamentals. The total amount of shareholder's equity as recorded on a company's balance sheet. View historical data for Elicio Therapeutics and its competitors. Elicio Therapeutics's current Total Stockholders Equity is $7.94 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Elicio Therapeutics stock overvalued right now?
Elicio Therapeutics (ELTX) has a current Total Stockholders Equity of $7.94 Mil. The current Total Stockholders Equity is $7.94 Mil. Elicio Therapeutics' overall GF Score™ is 26/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Stockholders Equity calculated?
Total Stockholders Equity is calculated from a company's financial statements. For Elicio Therapeutics (ELTX), the current Total Stockholders Equity is $7.94 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Elicio Therapeutics Business Description

Other Exchanges 9HA:Germany
Address 451 D Street, Suite 501, 5th Floor, Boston, MA, USA, 02210
Elicio Therapeutics Inc is a clinical-stage biotechnology company advancing novel immunotherapies for the treatment of cancer, including mKRAS-positive pancreatic cancer, colorectal cancer (CRC), lung cancer, and other mKRAS-positive cancers. The Company focuses on developing effective, off-the-shelf immunotherapies using its proprietary Amphiphile (AMP) technology, which aims to enhance the education, activation, and amplification of cancer-specific T cells to promote durable cancer immunosurveillance. Its clinical pipeline includes ELI-002 7P, a lymph node-targeted cancer immunotherapy currently being evaluated in a Phase 2 study for mKRAS pancreatic ductal adenocarcinoma (PDAC), a common form of pancreatic cancer.
26GF Score

Get the complete analysis for ELTX

Total Stockholders Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$2.84
Price